American Association for Cancer Research
crc-23-0512_fig3.png (494.12 kB)

FIGURE 3 from Cumulative Incidence, Risk Factors, and Overall Survival of Disease Recurrence after Curative Resection of Stage II–III Colorectal Cancer: A Population-based Study

Download (494.12 kB)
posted on 2024-02-29, 14:20 authored by Tara C. Boute, Hidde Swartjes, Marjolein J.E. Greuter, Marloes A.G. Elferink, Rik van Eekelen, Geraldine R. Vink, Johannes H.W. de Wilt, Veerle M.H. Coupé

Forest plot of risk for diagnosis with recurrent disease in patients with primary colon and rectal cancer, based on multivariable competing risk regression models. HR; Hazard ratio. ASA; American Society of Anesthesiologists. R0; resection margin of ≥1 mm. R1; resection margin of 0–1 mm. R2; macroscopically incomplete resection margin. IMVI; intramural vascular invasion. EMVI; extramural vascular invasion.


ZonMw (Netherlands Organisation for Health Research and Development)



Real-world data are necessitated to counsel patients about the risk for recurrent disease after curative treatment of colorectal cancer. This study provided a population-based overview of the epidemiology of recurrent disease in patients with surgically resected stage II/III colorectal cancer.Patients diagnosed with stage II/III primary colorectal cancer between July and December 2015 were selected from the Netherlands Cancer Registry (N = 3,762). Cumulative incidence of recurrent disease was estimated, and multivariable competing risk regression was used to identify risk factors for recurrent disease in patients with primary colon and rectal cancer. Moreover, overall survival (OS) after diagnosis of recurrent colorectal cancer was estimated.Median clinical follow-up was 58 months (Q1–Q3: 22–62). Five-year cumulative incidence of recurrent disease was 21.6% [95% confidence interval (CI): 20.0–23.2] and 30.0% (95% CI: 28.3–33.5) for patients with primary colon and rectal cancer, respectively. Stage III disease and incomplete resection margin in patients with primary colon cancer and extramural vascular invasion in patients with primary rectal cancer were strongly (HR ≥ 2) associated with recurrent disease. Median OS of patients with distant, locoregional, or the synchronous combination of distant and locoregional recurrent disease was 29, 27, and 13 months, respectively (P < 0.001). Patients with distant recurrences limited to liver or lung showed a median OS of 46 and 48 months, respectively. The incidence of recurrent disease was higher in patients with rectal cancer than in patients with colon cancer, predominantly due to higher rates of distant recurrences. OS after recurrent disease was impaired, but subgroups of patients diagnosed with recurrent disease limited to one site showed statistically significantly longer OS. Population-based data on recurrent colorectal cancer are rare, but crucial for counseling patients and their physicians. This large nationwide, population-based study provides an up-to-date overview of the epidemiology of recurrent disease in patients with stage II and III primary colon and rectal cancer treated with surgical resection.

Usage metrics

    Cancer Research Communications



    Ref. manager